What oral antibiotic regimen should be prescribed for a patient with intraoperative cultures growing Citrobacter freundii, Escherichia coli, and Enterococcus faecalis?

Oral Antibiotic Regimen for Polymicrobial Intra-Abdominal Infection

For intraoperative cultures growing Citrobacter freundii, E. coli, and Enterococcus faecalis, prescribe oral amoxicillin-clavulanate (875/125 mg twice daily) or oral fluoroquinolone (levofloxacin 750 mg daily) plus amoxicillin (500 mg three times daily) after transitioning from appropriate IV therapy, with the specific choice guided by susceptibility testing.

Treatment Algorithm

Step 1: Initial IV Therapy Based on Culture Results

Since you now have definitive culture data showing a polymicrobial infection with both gram-negative organisms (C. freundii, E. coli) and enterococci, your IV regimen must cover all three organisms:

• First-line IV option: Piperacillin-tazobactam (covers E. coli, most C. freundii, and E. faecalis) 1
• Alternative if resistance concerns: Carbapenem (meropenem or imipenem-cilastatin) - these maintain excellent activity against C. freundii and E. coli while covering enterococci 2, 3

Critical caveat: C. freundii has shown increasing resistance to third-generation cephalosporins (up to 70% resistance to some agents) and broad-spectrum penicillins, but remains uniformly susceptible to carbapenems 2, 3. If your patient received third-generation cephalosporins empirically, this may have selected for resistant C. freundii 2.

Step 2: Transition to Oral Therapy

Once the patient demonstrates clinical improvement (afebrile >24 hours, tolerating oral intake, normalizing white blood cell count), transition to oral antibiotics:

Preferred oral regimens based on susceptibilities:

• Amoxicillin-clavulanate 875/125 mg PO twice daily: Covers E. faecalis (ampicillin-susceptible enterococci) and many E. coli strains 1, 4

  • Check susceptibility for E. coli specifically, as resistance to ampicillin/sulbactam combinations has increased 5

• Fluoroquinolone (levofloxacin 750 mg daily) PLUS amoxicillin 500 mg three times daily:

  • Levofloxacin covers E. coli and C. freundii (which remains susceptible to newer fluoroquinolones) 2
  • Amoxicillin covers ampicillin-susceptible E. faecalis 4
  • Do NOT use this if local E. coli quinolone resistance exceeds 10% 1

• If multidrug resistance documented: Consider oral linezolid 600 mg twice daily for enterococcus coverage plus oral fluoroquinolone for gram-negatives (only if susceptible)

Step 3: Duration and Monitoring

• Total antibiotic duration: 4-7 days from source control (including IV days) for uncomplicated intra-abdominal infection with adequate source control 1
• Longer courses (7-14 days): Required if inadequate source control, immunosuppression, or high-severity infection 1

Key Evidence-Based Considerations

Enterococcal Coverage is Mandatory

The guidelines explicitly recommend antimicrobial therapy when enterococci are recovered from cultures, particularly in health care-associated infections 1. E. faecalis is typically ampicillin-susceptible, making aminopenicillins (amoxicillin, ampicillin) the preferred agents 1. Recent data confirms oral aminopenicillins are effective for uncomplicated E. faecalis infections with no increased treatment failure compared to IV therapy 4.

C. freundii Resistance Patterns

This organism poses specific challenges:

• Intrinsic AmpC β-lactamase production causes resistance to first, second, and many third-generation cephalosporins 3, 6
• Resistance to aminoglycosides and ciprofloxacin has increased markedly over time 3
• Carbapenems and fourth-generation cephalosporins (cefepime) maintain excellent activity 2, 3
• Newer fluoroquinolones (levofloxacin) remain effective 2

E. coli Considerations

While E. coli is typically susceptible to many agents, ESBL-producing strains occur in 9-17% of complicated intra-abdominal infections 7. Your susceptibility report is critical here - if ESBL-positive, avoid cephalosporins and fluoroquinolones; carbapenems become necessary 8.

Common Pitfalls to Avoid

1. Do not use third-generation cephalosporins alone - C. freundii will develop resistance during therapy through AmpC induction 2, 6

2. Do not omit enterococcal coverage - Guidelines specifically state antimicrobial therapy should be given when enterococci are recovered from cultures 1

3. Do not use fluoroquinolones without checking local resistance patterns - Many communities now have >10% E. coli quinolone resistance, making them inappropriate 1, 5

4. Do not forget metronidazole if anaerobic coverage is needed - Though not mentioned in your cultures, intra-abdominal infections often involve anaerobes requiring metronidazole addition to fluoroquinolone regimens 1, 5

5. Verify susceptibilities before finalizing oral regimen - The increasing multidrug resistance (up to 52.8% in some series) makes empiric choices risky without susceptibility data 9

Adjustments for High-Risk Patients

If your patient has APACHE II ≥15, immunosuppression, inadequate source control, or prolonged preoperative hospitalization (>5 days), maintain broader IV coverage longer before transitioning to oral therapy 1. These patients have higher failure rates and may require extended courses.